Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 09, 2023 08:00 ET | Source: Acrivon Therapeutics, Inc

Acrivon Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights

WATERTOWN, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision...
May 09, 2023 08:00 ET | Source: Acrivon Therapeutics, Inc

Acrivon Therapeutics Announces FDA Grants Fast Track Designation for Development of ACR-368 in Platinum-Resistant Ovarian Cancer and Endometrial Cancer

- In previous Phase 2 clinical trials involving more than 400 patients, ACR-368 produced deep, durable monotherapy responses, including complete responses, in a proportion of patients with solid...
April 25, 2023 08:00 ET | Source: Acrivon Therapeutics, Inc

Acrivon Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference

WATERTOWN, Mass., April 25, 2023 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision...
April 24, 2023 08:00 ET | Source: Acrivon Therapeutics, Inc

Acrivon Therapeutics to Host Virtual Investor Event on May 1, 2023

WATERTOWN, Mass., April 24, 2023 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision...
April 18, 2023 08:00 ET | Source: Acrivon Therapeutics, Inc

Acrivon Therapeutics to Present at the Stifel 2023 Targeted Oncology Days Conference

WATERTOWN, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision...
March 28, 2023 08:00 ET | Source: Acrivon Therapeutics, Inc

Acrivon Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights

WATERTOWN, Mass., March 28, 2023 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision...
March 06, 2023 08:00 ET | Source: Acrivon Therapeutics, Inc

Acrivon Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference

WATERTOWN, Mass., March 06, 2023 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision...
February 27, 2023 08:00 ET | Source: Acrivon Therapeutics, Inc

Acrivon Therapeutics to Participate on a Panel at Cowen’s 43rd Annual Health Care Conference

WATERTOWN, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision...
November 14, 2022 22:16 ET | Source: Acrivon Therapeutics, Inc

Acrivon Therapeutics Announces Pricing of Initial Public Offering

WATERTOWN, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision...
June 22, 2022 08:00 ET | Source: Acrivon Therapeutics

Acrivon Therapeutics Receives FDA Clearance for Innovative Phase 2 Trial to Treat Ovarian, Endometrial and Urothelial Cancer Patients Based on Predicted Sensitivity to ACR-368

--Pioneering trial will be using a first-of-its-kind OncoSignature® companion diagnostic to identify and treat patients that are predicted most likely to benefit from treatment— ...